Status:

COMPLETED

Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)

Lead Sponsor:

University Hospital, Basel, Switzerland

Conditions:

Healthy

Eligibility:

All Genders

25-65 years

Phase:

EARLY_PHASE1

Brief Summary

Serotonin receptors, especially the 5HT2A receptor, are thought to be involved in the effects of various recreationally used psychedelic substances such as LSD. LSD potently stimulates the 5-HT2A rece...

Eligibility Criteria

Inclusion

  • Age between 25 and 65 years.
  • Understanding of the German language.
  • Understanding the procedures and the risks associated with the study.
  • Participants must be willing to adhere to the protocol and sign the consent form.
  • Participants must be willing to refrain from taking illicit psychoactive substances during the study.
  • Participants must be willing to drink only alcohol-free liquids and no coffee, black or green tea, or energy drink after midnight of the evening before the study session, as well as during the study day.
  • Participants must be willing not to drive a traffic vehicle or to operate machines within 48 h after substance administration.
  • Women of childbearing potential must have a negative pregnancy test at the beginning of the study. Pregnancy tests are repeated before each study session.
  • Women of childbearing potential must be willing to use double-barrier birth control
  • Body mass index 18-29 kg/m2.

Exclusion

  • Chronic or acute medical condition
  • Current or previous major psychiatric disorder
  • Psychotic disorder in first-degree relatives
  • Illicit substance use (with the exception of cannabis) more than 10 times or any time within the previous two months.
  • Pregnant or nursing women.
  • Participation in another clinical trial (currently or within the last 30 days)
  • Use of medications that may interfere with the effects of the study medications (any psychiatric medications)
  • Tobacco smoking (\>10 cigarettes/day)
  • Consumption of alcoholic drinks (\>10/week)

Key Trial Info

Start Date :

November 28 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 11 2019

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT03321136

Start Date

November 28 2017

End Date

July 11 2019

Last Update

August 28 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital

Basel, Switzerland, 4031